Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kaltura Inc (KLTR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Kaltura IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Kaltura Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Kaltura Inc trades at $1.64 (market cap $250.18M), while Regeneron Pharmaceuticals Inc trades at $794 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 332.5× Kaltura Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.

KLTRREGN
Market Cap
$250.18M$83.19B
Sector
TechnologyHealth
52-Week High
$1.89$812.27
52-Week Low
$1.08$545.94
Enterprise Value
$262.40M$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kaltura Inc

Kaltura (KLTR) trades at $1.75, up 1.74% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue is stable around $181M, but the company remains unprofitable with a net margin of -6.92%. Positive cash flow from operations and industry recognitions for AI and video platforms highlight growth potential, though high debt and insider selling pose concerns.

The outlook is mixed: analyst consensus leans buy (44% buy ratings) on AI innovation and cash flow improvements, but risks include persistent losses, elevated valuation ratios, and competitive pressures. Investors should weigh cost control progress against profitability challenges for upside.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kaltura Inc

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)

Read more on KLTR

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN